Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report

References

• Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 1994;70(830):863–870.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Izumaru K, Nagata M, et al. The effect of low-dose corticosteroids on short- and long-term renal outcome in patients with cholesterol crystal embolism. Ren Fail. 2011;33(3):298–306.
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Sato T, Taguma Y. Low-density lipoprotein apheresis ameliorates renal prognosis of cholesterol crystal embolism. Ther Apher Dial. 2015;19(4):355–360.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases–positive and adverse effects. Arthritis Res Ther. 2014;16(Suppl 2):S2.
   PubMedGoogle Scholar
• Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Therapher Dial. 2003;7(4):382–390.
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolocumab (AMG 145) in statin-treated japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117(1):40–47.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57(7):769–779.
   PubMed Web of Science ®Google Scholar
• Tang ZH, Li TH, Peng J, et al. PCSK9: A novel inflammation modulator in atherosclerosis?. J Cell Physiol. 2019;234(3):2345–2355.
   PubMed Web of Science ®Google Scholar
• Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20(4):20.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–992.
   PubMed Web of Science ®Google Scholar
• Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650–1660.
   PubMed Web of Science ®Google Scholar
• Fries C, Roos M, Gaspert A, et al. Atheroembolic disease–a frequently missed diagnosis: results of a 12-year matched-pair autopsy study. Medicine (Baltimore). 2010;89(2):126–132.
   PubMed Web of Science ®Google Scholar
• Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease. Case report and review of the literature. Am J Nephrol. 1993;13(6):489–493.
   PubMed Web of Science ®Google Scholar
• Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33(5):840–850.
   PubMed Web of Science ®Google Scholar
• Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol. 2005;28(S2):S3–S11.
   PubMedGoogle Scholar
• Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36(6):1089–1109.
   PubMed Web of Science ®Google Scholar
• Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol. 2003;14(6):1584–1590.
   PubMed Web of Science ®Google Scholar
• Saku K, Zhang B, Noda K, et al. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493–1505.
   PubMed Web of Science ®Google Scholar
• Di Bartolo B, Scherer DJ, Brown A, et al. PCSK9 Inhibitors in hyperlipidemia: current status and clinical outlook. BioDrugs. 2017;31(3):167–174.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Bai XQ, Peng J, Wang MM, et al. PCSK9: a potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin Chim Acta. 2018;483:192–196.
   PubMed Web of Science ®Google Scholar
• Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway. Atherosclerosis. 2017;262:113–122.
   PubMed Web of Science ®Google Scholar
• Irace C, Carallo C, Scavelli F, et al. Influence of blood lipids on plasma and blood viscosity. Clin Hemorheol Microcirc. 2014;57(3):267–274.
   PubMed Web of Science ®Google Scholar
• Banyai S, Banyai M, Falger J, et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis. 2001;159(2):513–519.
   PubMed Web of Science ®Google Scholar
• Rubba P, Iannuzzi A, Postiglione A, et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 1990;81(2):610–616.
   PubMed Web of Science ®Google Scholar
• Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77(6):1925–1930.
   PubMed Web of Science ®Google Scholar
• Li X, Bayliss G, Zhuang S. Cholesterol crystal embolism and chronic kidney disease. Int J Mol Sci. 2017;18(6):E1120.
   Web of Science ®Google Scholar
• Konarzewski M, Szolkiewicz M, Sucajtys-Szulc E, et al. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol. 2014;40(2):157–163.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–2540.
   PubMed Web of Science ®Google Scholar